These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 23499431)

  • 21. Breaking down and building up alpha-synuclein: An insight on its N-terminal domain.
    Peqini K; Attanasio S; Feni L; Cappelletti G; Pellegrino S
    J Pept Sci; 2024 Apr; 30(4):e3556. PubMed ID: 38037257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mass Spectrometric Analysis of Lewy Body-Enriched α-Synuclein in Parkinson's Disease.
    Bhattacharjee P; Öhrfelt A; Lashley T; Blennow K; Brinkmalm A; Zetterberg H
    J Proteome Res; 2019 May; 18(5):2109-2120. PubMed ID: 30943367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered conformation of α-synuclein drives dysfunction of synaptic vesicles in a synaptosomal model of Parkinson's disease.
    Fonseca-Ornelas L; Viennet T; Rovere M; Jiang H; Liu L; Nuber S; Ericsson M; Arthanari H; Selkoe DJ
    Cell Rep; 2021 Jul; 36(1):109333. PubMed ID: 34233191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Purification of α-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity.
    Luth ES; Bartels T; Dettmer U; Kim NC; Selkoe DJ
    Biochemistry; 2015 Jan; 54(2):279-92. PubMed ID: 25490121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gangliosides, α-Synuclein, and Parkinson's Disease.
    Ledeen RW; Wu G
    Prog Mol Biol Transl Sci; 2018; 156():435-454. PubMed ID: 29747823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New insights into cellular α-synuclein homeostasis in health and disease.
    Dettmer U; Selkoe D; Bartels T
    Curr Opin Neurobiol; 2016 Feb; 36():15-22. PubMed ID: 26282834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transmissible α-synuclein seeding activity in brain and stomach of patients with Parkinson's disease.
    Thomzig A; Wagenführ K; Pinder P; Joncic M; Schulz-Schaeffer WJ; Beekes M
    Acta Neuropathol; 2021 Jun; 141(6):861-879. PubMed ID: 33895878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies.
    Poggiolini I; Erskine D; Vaikath NN; Ponraj J; Mansour S; Morris CM; El-Agnaf OMA
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34072869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibril breaking accelerates α-synuclein fibrillization.
    Shvadchak VV; Claessens MM; Subramaniam V
    J Phys Chem B; 2015 Feb; 119(5):1912-8. PubMed ID: 25582977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
    Ulusoy A; Febbraro F; Jensen PH; Kirik D; Romero-Ramos M
    Eur J Neurosci; 2010 Aug; 32(3):409-22. PubMed ID: 20704592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine quinones interact with alpha-synuclein to form unstructured adducts.
    Bisaglia M; Tosatto L; Munari F; Tessari I; de Laureto PP; Mammi S; Bubacco L
    Biochem Biophys Res Commun; 2010 Apr; 394(2):424-8. PubMed ID: 20226175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coordination and redox properties of copper interaction with α-synuclein.
    Valensin D; Dell'Acqua S; Kozlowski H; Casella L
    J Inorg Biochem; 2016 Oct; 163():292-300. PubMed ID: 27112900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.
    Sorrentino ZA; Vijayaraghavan N; Gorion KM; Riffe CJ; Strang KH; Caldwell J; Giasson BI
    J Biol Chem; 2018 Dec; 293(49):18914-18932. PubMed ID: 30327435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measuring Mitochondrial Dysfunction Caused by Soluble α-Synuclein Oligomers.
    Luth ES; Stavrovskaya IG
    Methods Mol Biol; 2019; 1948():183-198. PubMed ID: 30771178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk.
    Kayed R; Dettmer U; Lesné SE
    J Parkinsons Dis; 2020; 10(3):791-818. PubMed ID: 32508330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation and Inhibiting Microtubule Assembly.
    Oikawa T; Nonaka T; Terada M; Tamaoka A; Hisanaga S; Hasegawa M
    J Biol Chem; 2016 Jul; 291(29):15046-56. PubMed ID: 27226637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic Properties of Human α-Synuclein Related to Propensity to Amyloid Fibril Formation.
    Fujiwara S; Kono F; Matsuo T; Sugimoto Y; Matsumoto T; Narita A; Shibata K
    J Mol Biol; 2019 Aug; 431(17):3229-3245. PubMed ID: 31181290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane.
    Beyer K
    Cell Biochem Biophys; 2007; 47(2):285-99. PubMed ID: 17652776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A short motif in the N-terminal region of α-synuclein is critical for both aggregation and function.
    Doherty CPA; Ulamec SM; Maya-Martinez R; Good SC; Makepeace J; Khan GN; van Oosten-Hawle P; Radford SE; Brockwell DJ
    Nat Struct Mol Biol; 2020 Mar; 27(3):249-259. PubMed ID: 32157247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physicochemical characterization of the G51D mutation of α-synuclein that is responsible for its severe cytotoxicity.
    Murata T; Tochio N; Utsunomiya-Tate N
    Neurosci Lett; 2021 Aug; 760():136077. PubMed ID: 34161822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.